Skip to main content
. 2015 Jun 10;89(17):9115–9118. doi: 10.1128/JVI.01295-15

FIG 2.

FIG 2

In vivo therapeutic efficacies of HNIgGD5 and HNIgGH8 in mice. Mice received HNIgGD5 or HNIgGH8 24 h prior to H7N9 infection and were monitored daily for 14 days. (A) The survival rate is presented. (B) The average body weight change of the mice is shown. (C) Virus titers from nose and lung tissue were determined at 5 dpi. Virus titers were substantially reduced in the HuMAb-treated groups (P < 0.05, t test).